How does gbs happen

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Guillain-Barré syndrome (GBS) is an autoimmune disorder where the immune system attacks peripheral nerves, typically triggered by infections like Campylobacter jejuni (30-40% of cases) or viral illnesses. It causes rapid-onset muscle weakness, often starting in the legs and spreading upward, with about 20-30% of patients requiring mechanical ventilation due to respiratory muscle involvement. Most cases occur within days to weeks after an infection, and treatment includes intravenous immunoglobulin or plasma exchange to reduce severity.

Key Facts

GBS affects 1-2 people per 100,000 annually worldwide
Campylobacter jejuni infection precedes 30-40% of GBS cases
About 20-30% of patients require mechanical ventilation
Most patients (60-80%) recover fully within 6-12 months
First described by French physicians Georges Guillain and Jean Barré in 1916

Overview

Guillain-Barré syndrome (GBS) is a rare but serious autoimmune disorder that affects the peripheral nervous system, causing rapid muscle weakness and sometimes paralysis. First described in 1916 by French neurologists Georges Guillain and Jean Barré, along with their colleague André Strohl, the condition was initially called "acute inflammatory polyneuritis." GBS occurs worldwide, affecting approximately 1-2 people per 100,000 annually, with no significant gender or age predilection, though incidence increases slightly with age. The syndrome gained public attention during the 1976 U.S. swine flu vaccination campaign when a small increased risk was observed, though subsequent studies show most vaccines carry minimal risk. Historically, mortality rates were as high as 25% before modern intensive care, but today they've dropped to 3-7% in developed countries with proper treatment.

How It Works

GBS occurs when the body's immune system mistakenly attacks the peripheral nerves, specifically targeting the myelin sheath (the protective covering of nerve fibers) or, in some variants, the nerve axons themselves. This autoimmune response is typically triggered by a preceding infection, most commonly Campylobacter jejuni bacteria (responsible for 30-40% of cases), but also by viruses like cytomegalovirus, Epstein-Barr virus, or Zika virus. The immune system produces antibodies that cross-react with nerve components through molecular mimicry—where bacterial or viral antigens resemble nerve tissue proteins. This leads to inflammation, demyelination (damage to the myelin sheath), and impaired nerve signal transmission. Symptoms usually begin with tingling and weakness in the legs that spreads upward over hours to days, potentially affecting respiratory muscles. Diagnosis involves clinical examination, nerve conduction studies, and cerebrospinal fluid analysis showing elevated protein without increased white cells.

Why It Matters

GBS matters because it represents one of the most common causes of acute neuromuscular paralysis worldwide, with significant healthcare implications. Approximately 20-30% of patients require mechanical ventilation due to respiratory failure, making intensive care management crucial. While most patients (60-80%) recover fully within 6-12 months, about 20% experience persistent disability, and 3-7% die despite treatment. The condition has important public health connections, as seen with Zika virus outbreaks where GBS incidence increased 20-fold in affected regions. Understanding GBS mechanisms helps develop better treatments like intravenous immunoglobulin and plasma exchange, which reduce disability when administered early. Research continues on vaccines' rare association with GBS (estimated 1-2 additional cases per million flu vaccine doses) to ensure vaccine safety while maintaining public confidence in immunization programs.